Bago Laboratories Profile
Key Indicators
- Authorised Capital ₹ 4.85 M
as on 23-06-2024
- Paid Up Capital ₹ 4.81 M
as on 23-06-2024
- Company Age 22 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.40 M
as on 23-06-2024
- Revenue -19.72%
(FY 2022)
- Profit 6.97%
(FY 2022)
- Ebitda 12.97%
(FY 2022)
- Net Worth -4.81%
(FY 2022)
- Total Assets -11.46%
(FY 2022)
About Bago Laboratories
The Corporate was formerly known as Bgss Pharma Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.85 M and a paid-up capital of Rs 4.81 M.
The company currently has active open charges totaling ₹2.40 M.
Bala Thippabhotla and Vikram Bery serve as directors at the Company.
- CIN/LLPIN
U24239TG2002PTC038340
- Company No.
038340
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Jan 2002
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bago Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bala Thippabhotla  | Director | 01-May-2008 | Current |
Vikram Bery  | Director | 01-May-2008 | Current |
Financial Performance and Corporate Structure Insights of Bago Laboratories.
Bago Laboratories Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 19.72% decrease. The company also saw a slight improvement in profitability, with a 6.97% increase in profit. The company's net worth dipped by a decrease of 4.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bago Laboratories?
In 2020, Bago Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Apogen Remedies Private LimitedActive 13 years 5 monthsBala Thippabhotla and Vikram Bery are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Lakshmi Vilas Bank Ltd. Creation Date: 22 Nov 2002 | ₹1.20 M | Open |
The Lakshmi Vilas Bank Ltd. Creation Date: 22 Nov 2002 | ₹1.20 M | Open |
How Many Employees Work at Bago Laboratories?
Unlock and access historical data on people associated with Bago Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bago Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bago Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
